(Q37188995)

18 August 2017

1 reference

title

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal (English)

1 reference

18 August 2017

1 reference

1 reference

Benedicto Crespo-Facorro

3

object named as

Benedicto Crespo-Facorro

0 references

Mario Alvarez-Jiménez

object named as

Mario Alvarez-Jiménez

1

0 references

author name string

César González-Blanch

2

1 reference

18 August 2017

Sarah Hetrick

4

1 reference

18 August 2017

Jose Manuel Rodríguez-Sánchez

5

1 reference

18 August 2017

Rocio Pérez-Iglesias

6

1 reference

18 August 2017

Jose Luis Vázquez-Barquero

7

1 reference

18 August 2017

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

22

1 reference

18 August 2017

7

1 reference

18 August 2017

547-562

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200822070-00002

18 August 2017

0 references

cites work

Differential effect of clozapine on weight: a controlled study

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200822070-00002

Stigmatisation of people with mental illnesses

21 January 2018

1 reference

12 December 2020

Amoxapine as an atypical antipsychotic: a comparative study vs risperidone

1 reference

12 December 2020

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

1 reference

12 December 2020

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

1 reference

12 December 2020

Review of atypical antipsychotics and weight gain.

1 reference

12 December 2020

Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial

1 reference

12 December 2020

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

1 reference

12 December 2020

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

1 reference

12 December 2020

The impact of weight gain on quality of life among persons with schizophrenia.

1 reference

12 December 2020

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

1 reference

12 December 2020

Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.

1 reference

12 December 2020

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Social and economic consequences of overweight in adolescence and young adulthood

1 reference

12 December 2020

Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia

1 reference

12 December 2020

Schizophrenia and obesity: impact of antipsychotic medications.

1 reference

12 December 2020

Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.

1 reference

12 December 2020

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

12 December 2020

Physical health monitoring of patients with schizophrenia

1 reference

12 December 2020

Medication adherence of individuals with a first episode of psychosis

1 reference

12 December 2020

Weight and blood pressure change during clozapine treatment

1 reference

12 December 2020

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

1 reference

12 December 2020

Metabolic syndrome and schizophrenia

1 reference

12 December 2020

Antipsychotic-induced weight gain and therapeutic response: a differential association.

1 reference

12 December 2020

Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia

1 reference

12 December 2020

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

12 December 2020

Weight gain from novel antipsychotic drugs: need for action

1 reference

12 December 2020

Quality-of-care research: internal elegance and external relevance

1 reference

12 December 2020

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

12 December 2020

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

12 December 2020

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Obesity as a risk factor for antipsychotic noncompliance.

1 reference

12 December 2020

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial

1 reference

12 December 2020

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

1 reference

12 December 2020

Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia

1 reference

12 December 2020

Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials.

1 reference

12 December 2020

Susceptibility genes for the side effect of antipsychotics on body weight and obesity

1 reference

12 December 2020

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

1 reference

12 December 2020

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

1 reference

12 December 2020

Epidemiology, morbidity, and treatment of overweight and obesity.

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

12 December 2020

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

1 reference

12 December 2020

Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol

1 reference

12 December 2020

The association between weight change and psychological well-being in women

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia

1 reference

12 December 2020

Antipsychotic-induced weight gain: a review of the literature

1 reference

12 December 2020

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

12 December 2020

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

12 December 2020

Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study

1 reference

12 December 2020

A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

1 reference

12 December 2020

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

1 reference

12 December 2020

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Weight gain in first-episode psychosis

1 reference

12 December 2020

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

12 December 2020

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

1 reference

12 December 2020

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

12 December 2020

Neuroleptics and quality of life. A patient survey

1 reference

12 December 2020

Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial.

1 reference

12 December 2020

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

1 reference

12 December 2020

A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months

1 reference

12 December 2020

Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial

1 reference

12 December 2020

Olanzapine treatment of residual positive and negative symptoms

1 reference

12 December 2020

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

1 reference

12 December 2020

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

1 reference

12 December 2020

Weight gain in first-episode psychosis over three years

1 reference

12 December 2020

Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population

1 reference

12 December 2020

Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.

1 reference

12 December 2020

10.2165/00023210-200822070-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference